Graphite Bio, Inc. Profile Avatar - Palmy Investing

Graphite Bio, Inc.

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly co…

Biotechnology
US, South San Francisco [HQ]

Risk Factors

By Management
Not Available

    No Risk Factor available yet. You can request "Risk Factors" through an email.

End of GRPH's Analysis
CIK: 1815776 CUSIP: 38870X104 ISIN: US38870X1046 LEI: - UEI: -
Secondary Listings
GRPH has no secondary listings inside our databases.